Research Article
Discovery and Validation of Circulating EVL mRNA as a Prognostic Biomarker in Pancreatic Cancer
Table 1
The expression of EVL and clinicopathologic features in 79 pancreatic cancer patients.
| Characteristics | EVL | value (χ2 test) | Low expression | High expression |
| Age | | | 0.010 | ≦60 | 6 | 16 | | >60 | 34 | 23 | |
| Gender | | | 0.556 | Male | 18 | 15 | | Female | 22 | 24 | |
| T classification | | | 0.417 | I, II | 21 | 24 | | III, IV | 19 | 15 | |
| N classification | | | 0.516 | No | 26 | 28 | | Yes | 14 | 11 | |
| Metastasis | | | 1.000 | No | 37 | 37 | | Yes | 3 | 2 | |
| Clinical stage | | | 0.260 | I, II | 31 | 34 | | III, IV | 9 | 5 | |
| Pathological differentiation | | 0.007 | | 1, 2 | 19 | 30 | | 3, 4 | 21 | 9 | |
| Vessel invasion | | | 0.106 | No | 33 | 26 | | Yes | 7 | 13 | |
| Nerve invasion | | | 0.406 | No | 9 | 12 | | Yes | 31 | 27 | |
|
|